Look for Sequenom, Inc. (NASDAQ: SQNM) to be smacked hard by selling pressure today. Late Wednesday, the company reported that improper handling of research and development test data and results by its employees has delayed the launch of its Down's Syndrome test. Sequenom said it's forming a special committee to investigate employee activity related to the tainted test data.

The company's SEQureDx tests the DNA of a fetus, via the mother's blood, in order to determine whether their blood groups are compatible. Although Sequenom can no longer rely on previously announced test data and results, Chief Executive Harry Stylli asserted, "We are not back at square one" on a conference call.

Continue reading Sequenom spirals lower on Down's Syndrome test delay

Sequenom spirals lower on Down's Syndrome test delay originally appeared on BloggingStocks on Thu, 30 Apr 2009 10:20:00 EST. Please see our terms for use of feeds.